Healthy volunteers in US phase I clinical trials: Sociodemographic characteristics and participation over time.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
05
2021
accepted:
20
08
2021
entrez:
7
9
2021
pubmed:
8
9
2021
medline:
17
11
2021
Statut:
epublish
Résumé
Increasing the diversity of research participants is an important focus of clinical trials. However, little is known regarding who enrolls as healthy volunteers in Phase I clinical trials, which test the safety and tolerability of investigational new drugs. Despite the risk, healthy volunteers can derive no medical benefit from their participation, and they are financially compensated for enrolling. This study's purpose is to describe sociodemographic characteristics and clinical trial participation histories of healthy people who enroll in US Phase I trials. The HealthyVOICES Project (HVP) is a longitudinal study of healthy individuals who have enrolled in Phase I trials. We describe self-reported sociodemographic information and Phase I trial history from HVP recruitment (May-December 2013) through the project's end three years later (December 2016). Trial experiences are presented as medians and quartiles. The HVP included 178 participants. Nearly three-fourths of participants were male, and two-thirds were classified as racial and ethnic minorities. We found that some groups of participants were more likely to have completed a greater number of clinical trials over a longer timeframe than others. Those groups included participants who were male, Black, Hispanic, 30-39-years-old, unemployed, had received vocational training in a trade, or had annual household incomes of less than $25,000. Additionally, the greater the number of clinical trials participants had completed, the more likely they were to continue screening for new trials over the course of three years. Participants who pursued clinical trials as a full-time job participated in the greatest number of trials and were the most likely to continuing screening over time. Participation as a healthy volunteer in US Phase I trials is driven by social inequalities. Disadvantaged groups tend to participate in a greater number of clinical trials and participate longer than more privileged groups.
Sections du résumé
BACKGROUND
Increasing the diversity of research participants is an important focus of clinical trials. However, little is known regarding who enrolls as healthy volunteers in Phase I clinical trials, which test the safety and tolerability of investigational new drugs. Despite the risk, healthy volunteers can derive no medical benefit from their participation, and they are financially compensated for enrolling.
OBJECTIVE
This study's purpose is to describe sociodemographic characteristics and clinical trial participation histories of healthy people who enroll in US Phase I trials.
METHODS
The HealthyVOICES Project (HVP) is a longitudinal study of healthy individuals who have enrolled in Phase I trials. We describe self-reported sociodemographic information and Phase I trial history from HVP recruitment (May-December 2013) through the project's end three years later (December 2016). Trial experiences are presented as medians and quartiles.
RESULTS
The HVP included 178 participants. Nearly three-fourths of participants were male, and two-thirds were classified as racial and ethnic minorities. We found that some groups of participants were more likely to have completed a greater number of clinical trials over a longer timeframe than others. Those groups included participants who were male, Black, Hispanic, 30-39-years-old, unemployed, had received vocational training in a trade, or had annual household incomes of less than $25,000. Additionally, the greater the number of clinical trials participants had completed, the more likely they were to continue screening for new trials over the course of three years. Participants who pursued clinical trials as a full-time job participated in the greatest number of trials and were the most likely to continuing screening over time.
IMPLICATIONS
Participation as a healthy volunteer in US Phase I trials is driven by social inequalities. Disadvantaged groups tend to participate in a greater number of clinical trials and participate longer than more privileged groups.
Identifiants
pubmed: 34492044
doi: 10.1371/journal.pone.0256994
pii: PONE-D-21-15204
pmc: PMC8423261
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0256994Subventions
Organisme : NHLBI NIH HHS
ID : K01 HL146900
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM099952
Pays : United States
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Econ Soc. 2015;44(4):545-566
pubmed: 27524854
Clin Trials. 2017 Oct;14(5):526-536
pubmed: 28783972
J Empir Res Hum Res Ethics. 2018 Dec;13(5):494-510
pubmed: 30296882
Work Employ Soc. 2020 Jun;34(3):441-456
pubmed: 32431474
J Empir Res Hum Res Ethics. 2015 Feb;10(1):65-75
pubmed: 25742668
Scand J Work Environ Health. 2021 Apr 1;47(3):171-180
pubmed: 33283874
J Womens Health (Larchmt). 2018 Apr;27(4):418-429
pubmed: 29048983
Am J Bioeth. 2001 Spring;1(2):51-3
pubmed: 11951892
Clin Trials. 2017 Oct;14(5):537-546
pubmed: 28766409
Soc Psychol Q. 2016 Sep;79(3):222-242
pubmed: 28867852
J Med Philos. 2018 Jan 12;43(1):83-114
pubmed: 29342285
New Yorker. 2008 Jan 7;:36-41
pubmed: 18265451
J Bioeth Inq. 2019 Dec;16(4):535-549
pubmed: 31713712
Sociol Inq. 2018 Nov;88(4):724-748
pubmed: 30546162
Sociol Health Illn. 2015 Jan;37(1):127-42
pubmed: 25601069
Perspect Biol Med. 2003 Fall;46(4):508-20
pubmed: 14593220
J Cult Econ. 2021;14(4):464-484
pubmed: 34239602
PLoS Med. 2018 Nov 20;15(11):e1002698
pubmed: 30457992
Crit Public Health. 2020;30(2):141-152
pubmed: 32123487
Clin Pharmacol Ther. 2007 Aug;82(2):219-27
pubmed: 17410122
Kennedy Inst Ethics J. 2013 Dec;23(4):355-79
pubmed: 24552076
Account Res. 1999;7(1):3-20
pubmed: 11657561
Am J Public Health. 2014 Feb;104(2):e16-31
pubmed: 24328648
Am J Ther. 2015 Nov-Dec;22(6):435-55
pubmed: 25621972
N Engl J Med. 2008 May 29;358(22):2316-7
pubmed: 18509119
Clin Trials. 2021 Aug;18(4):477-487
pubmed: 33938244
Am J Public Health. 2011 Dec;101(12):2217-22
pubmed: 22021285
Eur J Clin Pharmacol. 2007 Nov;63(11):1085-94
pubmed: 17891536